Table 1: The mean level and standard deviations of thyroid gland function tests in both groups.

|  |  |  |  |
| --- | --- | --- | --- |
| Group | Thyroid function tests | | |
| TSH (mIU/L) | Free T4 (mcg/dL) | Free T3 (pg/mL) |
| Study | 6.87±0.54 | 2.63±0.18 | 1.9±0.43 |
| Control | 1.9±0.23 | 7.6±1.1 | 3.6±0.56 |

Table 2: The prevalence of the clinical presentations of OLP and the mean serum levels of TPOAb (IU/ml) and IL-8 (pg/ml) in the study and control groups.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Group | Type of OLP | | Serum markers | | Markers’ correlation |
| EOLP  No. (%) | NEOLP  No. (%) | TPOAb | IL-8 |
| Study | 30 (65.4%) | 16 (34.6%) | 90.3±18.8b | 12.39 ± 2.65a | r=0.783 p=0.001 |
| Control | 14 (30.5%) | 32 (69.5%) | 11±4.8b | 3.9±1.7a | P=0.65 |

Table 3: The mean levels of serum positive\* TPOAb and IL-8 (pg/ml) serum levels in patients with EOLP and NEOLP

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| OLP (n=46)\* | TPOAb posit.\*\* / negat. (%) | TPOAb posit. /EOLP  OR [95% CI] | Serum IL-8 level (pg/ml)±SD | IL-8 levels/EOLP  OR [95% CI] |
| EOLP (n=44) | 30 /14  (68/31) | 4.02  [1.21 - 13.4]  (P = 0.023) | 10.45±4.1\* | 1.276  [1.092 - 1.49]  (P=0.002) |
| NEOLP (n=48) | 16/32  (33/66) | 6.04±3.93 \* |

\*: Study and control groups

\*\*: Values higher than 35 IU/mL (All 46 were of the study group)